VEGF as a potential target in lung cancer

Frezzetti Daniela; Gallo Marianna; Maiello Monica R.; DAlessio Amelia; Esposito Claudia; Chicchinelli Nicoletta; Normanno Nicola; De Luca Antonella

首页> 外文期刊>Expert opinion on therapeutic targets >VEGF as a potential target in lung cancer

【24h】

VEGF as a potential target in lung cancer

机译：VEGF作为肺癌的潜在目标

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction The vascular endothelial growth factor A ( VEGF) is the main mediator of angiogenesis. In addition, VEGF contributes to cancer growth and metastasis directly targeting tumor cells. VEGF overexpression and/or high VEGF serum levels have been reported in lung cancer.

机译：引言血管内皮生长因子A（VEGF）是血管生成的主要介体。此外，VEGF有助于直接靶向肿瘤细胞的癌症生长和转移。肺癌报道了VEGF过表达和/或高VEGF血清水平。

著录项

来源
《Expert opinion on therapeutic targets》 |2017年第12期|共8页
作者
Frezzetti Daniela; Gallo Marianna; Maiello Monica R.; DAlessio Amelia; Esposito Claudia; Chicchinelli Nicoletta; Normanno Nicola; De Luca Antonella;
展开▼
作者单位

Fdn G Pascale IRCCS Ist Nazl Tumori Cell Biol &

Biotherapy Unit Via Mariano Semmola I-80131;

Fdn G Pascale IRCCS Ist Nazl Tumori Cell Biol &

Biotherapy Unit Via Mariano Semmola I-80131;

Fdn G Pascale IRCCS Ist Nazl Tumori Cell Biol &

Biotherapy Unit Via Mariano Semmola I-80131;

Fdn G Pascale IRCCS Ist Nazl Tumori Cell Biol &

Biotherapy Unit Via Mariano Semmola I-80131;

Fdn G Pascale IRCCS Ist Nazl Tumori Cell Biol &

Biotherapy Unit Via Mariano Semmola I-80131;

Fdn G Pascale IRCCS Ist Nazl Tumori Cell Biol &

Biotherapy Unit Via Mariano Semmola I-80131;

Fdn G Pascale IRCCS Ist Nazl Tumori Cell Biol &

Biotherapy Unit Via Mariano Semmola I-80131;

Fdn G Pascale IRCCS Ist Nazl Tumori Cell Biol &

Biotherapy Unit Via Mariano Semmola I-80131;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
Vascular endothelial growth factor; lung cancer; anti-VEGF therapies; tumor cells;

机译：血管内皮生长因子;肺癌;抗VEGF疗法;肿瘤细胞;

相似文献

外文文献
中文文献
专利

1. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling [J] . Chen Huanjun, Cong Qifei, Du Zhenyun, Cancer letters . 2016,第1期

机译：硫酸岩藻依聚糖FP08S2通过靶向VEGFR2 / VEGF并阻断VEGFR2 / Erk / VEGF信号传导破坏血管生成，从而在体内抑制肺癌细胞的生长
2. Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials [J] . Sha’Shonda L. Revels, Jay M. Lee Journal of Thoracic Disease . 2018,第2期

机译：靶向VEGF受体（VEGFR）的酪氨酸激酶抑制（TKI）中的抗血管生成治疗（NSCLC）：靶向VEGF受体（VEGFR）：III期临床试验的透视
3. VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach [J] . Barr Martin P., OByrne Kenneth J., Al-Sarraf Nael, Epigenomics . 2015,第6期

机译：非小细胞肺癌中VEGF介导的细胞存活：对VEGF受体表观遗传靶向的治疗方法
4. PHOSPHOPROTEOMICS OF NON-SMALL-CELL LUNG CANCER CELLS TREATED WITH ERLOTINIB REVEALS DRUG-RESISTANT SIGNATURES AND POTENTIAL TARGETS [C] . Jun Adachi, Yuichi Abe, Maiko Nagano, International Mass Spectrometry Conference . 2018

机译：用厄洛替尼处理的非小细胞肺癌细胞的磷脂蛋白酶揭示了耐药象征和潜在目标
5. RhoA as a Potential Target in Lung Cancer. [D] . Zandvakili, Inuk. 2015

机译：RhoA作为肺癌的潜在靶标。
6. Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials [O] . Sha’Shonda L. Revels, Jay M. Lee 2018

机译：非鳞状非小细胞肺癌（NSCLC）的靶向VEGF受体（VEGFR）的酪氨酸激酶抑制（TKI）的抗血管生成治疗：III期临床试验的观点
7. MiR-200c increases the radiosensitivity of non-small-cell lung cancer cell line A549 by targeting VEGF-VEGFR2 pathway. [O] . Liangliang Shi, Sheng Zhang, Hongge Wu, 2013

机译：miR-200c通过靶向VEGF-VEGFR2途径增加非小细胞肺癌细胞系a549的放射敏感性。

VEGF as a potential target in lung cancer

摘要

著录项

相似文献

相关主题

期刊订阅